The Protective Effects A Full-term Pregnancy Plays Against Mammary Carcinoma by Carter, Matthew p
University of Massachusetts Amherst
ScholarWorks@UMass Amherst
Masters Theses 1911 - February 2014
2010
The Protective Effects A Full-term Pregnancy Plays
Against Mammary Carcinoma
Matthew p. Carter
University of Massachusetts Amherst
Follow this and additional works at: https://scholarworks.umass.edu/theses
Part of the Genetic Phenomena Commons
This thesis is brought to you for free and open access by ScholarWorks@UMass Amherst. It has been accepted for inclusion in Masters Theses 1911 -
February 2014 by an authorized administrator of ScholarWorks@UMass Amherst. For more information, please contact
scholarworks@library.umass.edu.
Carter, Matthew p., "The Protective Effects A Full-term Pregnancy Plays Against Mammary Carcinoma" (2010). Masters Theses 1911 -
February 2014. 415.
Retrieved from https://scholarworks.umass.edu/theses/415
THE PROTECTIVE EFFECTS A FULL-TERM PREGNANCY PLAYS AGAINST 
MAMMARY CARCINOMA 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A Thesis Presented  
 
by 
 
 MATTHEW P CARTER  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Submitted to the Graduate School of the  
University of Massachusetts Amherst in partial fulfillment  
of the requirements for the degree of 
 
MASTER OF SCIENCE  
 
May 2010 
 
Molecular and Cellular Biology  
THE PROTECTIVE EFFECTS A FULL-TERM PREGNANCY PLAYS AGAINST 
MAMMARY CARCINOMA  
 
A Thesis Presented  
 
by 
  
MATTHEW P. CARTER 
 
 
 
 
 
 
 
 
 
 
 
 
Approved by:  
 
_____________________________  
Sallie Smith-Schneider, Chair  
 
_____________________________  
Joseph Jerry, Member  
 
_____________________________  
Alan Schneyer, Member  
 
 
 
 
 
 
 
 
 
______________________________  
David Gross, Director  
Program in Molecular and Cellular Biology  
iii 
 
ACKNOWLEDGEMENTS  
 
 
First and foremost I would like to thank my thesis advisor Sallie Smith-Schneider 
for all of her patience and support. She allowed me a great deal of freedom in my 
scientific endeavors and taught me a lot about science and life in general. I would also 
like to extend my gratitude towards the other two members of my committee Joseph 
Jerry, and Alan Schneyer for their helpful comments and suggestions on all stages of this 
project.  
A special thank you to all those who’s support and friendship helped me to stay 
focused on this project and provided me with the encouragement to continue when the 
going got tough.  
 
 
 
 
 
 
 
 
 
 
 
 
 
iv 
 
ABSTRACT 
 
THE PROTECTIVE EFFECTS A FULL-TERM PREGNANCY PLAYS AGAINST 
MAMMARY CARCINOMA 
 
MAY 2010 
 
MATTHEW P. CARTER, B.S., UNIVERSITY OF MASSACHUSETTS, AMHERST 
 
Directed by: Professor Sallie Smith/Schneider PhD 
 
 Countless epidemiological studies have consistently shown that a full-term 
pregnancy conveys a significant reduction in the lifetime risk of developing breast 
cancer. We chose to study healthy breast tissue from parous and nulliparous women 
undergoing reduction mammoplasty surgery. By doing high throughput microarray 
analyses, we attempted to identify potential genes that are differentially regulated in 
response to a full term pregnancy. The genes suggested by our microarray were diverse in 
function. Many of our subsequent PCR assays were done on genes involved in DNA 
damage response (DDR). More specifically, many genes encompassing the nucleotide 
excision repair (NER) pathway were found to be significantly upregulated in the parous 
breast, and could provide a mechanism conveying protection against breast cancer. 
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CHAPTER 1 
INTRODUCTION 
 
 
Parity Induced Protection against Breast Cancer 
Breast cancer remains the second leading cause of death among women despite 
our advances in understanding and treating the disease. In 2007 alone, more than 178,000 
new cases of breast cancer were diagnosed, and an estimated 40,460 additional deaths are 
believed to result from these diagnoses (Jemal et. al 2009). Epidemiological studies have 
identified many different factors which pose both a positive and negative risk against 
breast cancer. Such factors include age, geographic location, socioeconomic status, 
familial history of breast cancer, mammographic density, history of benign breast disease, 
ionizing radiation, bone density, height, IGF-1 and prolactin levels, and chemopreventive 
agents (Dumitrescu et. al 2005). Countless epidemiological studies have also consistently 
shown that a full-term pregnancy conveys a significant reduction in the lifetime risk of 
developing breast cancer regardless of many of these aforementioned risk factors. It was 
first reported that women who underwent a full-term pregnancy before the age of 20 
enjoy half the risk of developing breast cancer over the course of their life when 
compared to nulliparous women (Macmahon 1970). Conversely, parity has also been 
reported to simultaneously increase the short-term risk of developing cancer immediately 
following childbirth (Lambe et al 1994). This long-term parity protective effect is a 
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powerful observation, and it is a phenotype that must be conveyed molecularly. This 
project was aimed at further elucidating this molecular basis. 
 Microarray analyses of laser-dissected epithelium from parous women have 
produced a transcriptomic signature corresponding with a deregulated expression of an 
eclectic panel of genes involved in DNA damage repair, programmed cell death, immune 
surveillance, and growth regulation to name a few (Russo et al 2006). Although many of 
these studies have been instrumental to further identifying the genetic basis of this 
reduced risk, they neglect any genes not directly found in the epithelial portion of 
mammary tissue. The human breast is comprised of, and stratified by several different 
types of tissue: a dense stromal layer that encircles the epithelium, and a diffuse adipose 
fraction that further surrounds the stroma. Our study is important in this respect, because 
our fingerprint should be more encompassing of any of the important players within and 
beyond the epithelial component of the mammary gland. Further identification of this 
parity-induced fingerprint in the mammary gland is indispensable as it will further 
elucidate the mechanisms by which early parous women are much less likely to develop 
breast cancer over their lifetime. Ultimately, this identification could serve as the basis 
for developing new target-based chemotherapeutic therapies. 
 
 
 
             Rodent models have proven indispensible to elucidating the basis of the 
protection conveyed by a full-term pregnancy. The first important transformation of the 
rodent mammary gland occurs during maturation. Cap cells are a population of basal-like 
epithelial cells responsible for the ductal outgrowths seen during maturation of the 
Rodent Models and Their Signficance as a Model 
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mammary glands. These cap cells are found distally in the lobules, at the apex of the 
duct. Cap cells in this apical region are multipotent as they progressively alter in 
morphology and gradually transform into a mature myoepithelial species. Cap cells 
eventually infiltrate the stroma, this becomes one of the termination cues for ductal 
elongation that occurs during puberty (Williams et al 1983). Cap cells can therefore be 
defined as a stem cell population that serves as a reservoir from which new basal and 
myoepithelial cells can arise during ductal morphogenesis and elongation (Williams et al. 
1982). 
 The second radical transformation of the rodent mammary gland occurs during 
pregnancy. During gestation, there is a robust period of proliferation and differentiation 
and maximal growth occurs at parturition when the gland is ready for lactation. In rodent 
models, this change in architecture in the mammary gland has been shown to be 
somewhat permanent and can be appreciated even after 21 days of lactation, and 28 days 
of post-
lactational 
involution 
(Figure 1.1). It 
was 
demonstrated 
that a full-term 
pregnancy in 
Sprague Dawley rats causes a shift in the cell-cycle profile and ultimately leads to 
differentiation in the mammary gland and thereby prevents the initiation of cancer (Russo 
Figure 1.1 - Carmine stained mammary glands from Sprague 
Dawley Rats and two different strains of mice. Glands represent 
ductal architecture after 28 days of post-lactational involution 
evidencing that the architectural changes are permanent. D’cruz 
et al 2008 
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et. al 1980). We also know that the same protective effect can be conveyed chemically by 
treating virgin rats with the placental hormone Human Chorionic Gonadotropin (hCG) as 
well as the ovarian hormones Estrogen and Progesterone (E&P) (Russo et. al 1990, 
Swanson et. al 1997). We know that hCG (a pregnancy hormone) protects the mammary 
gland against chemically-induced carcinogenesis where upon binding it’s receptor it 
causes transcription of a vast panel of genes which act to differentiate the mammary 
epithelium. More specifically, hCG induces the synthesis of Inhibin A and Inhibin B 
mRNAs,  and hCG causes the downregulation of Estrogen Receptor alpha (ERa) by 
methylation of CpG islands (Srivastava et. al 1999, and Russo et. al 2007). It was shown 
that mice with a complete deletion in the βB subunit have severely depleted ductal 
outgrowths during pregnancy, and can never effectively lactate after birth (Robinson and 
Hennighausen, 1997). 
 This persistent change in the ductal architecture is also accompanied by a 
radically different transcriptional fingerprint that lasts over the life of the animal (D’cruz 
et al 2008). A total of 14 genes with a diverse set of functions (eg. Growth factors, cell 
metabolism enzymes, immune factors, and cell adhesion molecules, etc), were found to 
be differentially regulated in response to parity. These same genes could be used as 
predictors to blindly discern between parous and nulliparous animals of the same age 
(D’cruz et. al 2008). 
Although rodent studies have been instrumental in identifying the molecular 
players and dissecting the pathways conveying this parity protective effect, human 
mammary tissue is the most relevant system to study as it directly relates to human breast 
cancer. With this in mind, it is tremendously difficult to find specimens of human 
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mammary tissue that all fit into a specific paradigm because these populations of women 
tend to have significant variations in reproductive history, as well unique lifestyles and 
environments (J. Russo et al 1988). Although this reproductive history could be fairly 
accurately assessed by the information from our post-operative interview, many other 
factors such as race, ethnicity, diet, BMI, point of estrous, etc., could act as confounding 
variables. 
 
 
Experimental approaches to identifying signatures 
 Our first approach to identifying molecular players was done by studying normal 
snap-frozen mammary tissue from reduction mammoplasties. By convention, we called 
these reduction tissues time 0 (T=0) based on the fact they represent the tissues without 
any experimental treatment. Patient mammary tissue was selected, age matched, and 
RNA was isolated from these specimens and a sent for microarray analysis. A heatmap 
was created showing genes that were differentially regulated in response to parity. In 
order to validate data generated from our microarrays, RNA was re-isolated from the 
same patients’ mammary tissue, cDNAs were created, and Quantitative Polymerase 
Chain Reaction (QPCR) experiments were performed. In several cases, these 
differentially regulated genes were assessed at the level of protein by IHC. 
           In our second approach, we hypothesized that we could identify molecular 
pathways altered by a full-term pregnancy by comparing responses in gene expression of 
mammary tissue from parous and nulliparous women in response to ionizing radiation. 
For our experiments, we chose ionizing radiation (γIR) to perturb the explants because it 
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is well-recognized as a potent carcinogen in the mammary gland that causes mutations by 
directly causing double-stranded DNA breaks (DSBs). Ionizing radiation has also been 
shown to indirectly affect cells by means of “bystander effects.” For example, selectively 
irradiating a single human fibroblast causes cell damage to another 80-100 adjacent 
unirradiated fibroblasts in vitro (Belyakov et. al 2001). Bystander effects are well- 
characterized by the exchange and rearrangement of chromosomes, as well mutations, 
apoptosis, genomic instability (Morgan 2003). Bystander effects aren’t necessarily 
detrimental to tissues and may actually serve as mechanism by which the stroma can 
survey and protect the gland from excessive damage. It’s been reported that bystander 
cells show a robust proliferative response while simultaneously secreting growth 
inhibitory factors to adjacent tissues (Gerashchenko2005, Komarova 1998). γIR has been 
crucial to this study because it allows us to expose mammary gland to an acute 
carcinogenic event and examine the ways these tissues differentially respond to stress as 
a function of the patient’s parity status. In addition to looking at the molecular players 
affected by IR, we also wished to test if the parous mammary gland was more or less 
sensitive to death by TUNEL assay.  
This second approach differs from the first in the respect that we are observing 
how the parous breast differentially responds to carcinogenic stress. Conversely, our first 
approach represents a method to look at basal levels of transcripts that might be 
differentially regulated in the parous breast. 
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CHAPTER 2 
PUTATIVE MOLECULAR PLAYERS CONVEYING THE PARITY-
PROTECTIVE EFFECT AGAINST BREAST CANCER  
 
 
 
 
Introduction 
Involvement of Growth Factors Affected By Parity 
Intuitively, growth factors (both growth promoting and inhibitory) should be an 
incredibly important family of genes affected by a full-term pregnancy as the mammary 
gland is marked phenotypically by a radical outgrowth followed by a marked involution. 
Members of and related to the Insulin-like Growth Factors (IGFs) have been shown to be 
permanently deregulated in response to parity. Insulin-like Growth Factor 2 Receptor 
IGF2R, Insulin-like growth factor binding protein 4 IGFBP4, and IGFBP7 have shown to 
be persistently upregulated in the parous mammary gland (Russo 2005).  
Transforming growth factor-beta (TGF-β) is a multifunctional family of cytokines 
that regulates tissue development as well as repair processes. Many different members of 
and related to this family have been identified as possible players conveying this parity-
protective effect in humans as well as rodents. Latent transforming growth factor β 
binding protein 4 (LTBP4) was shown to be significantly upregulated in the parous breast 
(Russo et al 2008). The ligand TGFβIII was shown to be upregulated in mammary gland 
of parous rodents (D’cruz et al 2002).  Type III TGF-β receptor (TβRIII) is 
downregulated in a wide range of human cancers, including breast cancer. TβRIII is well 
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supported in the literature as a bona fide tumor suppressor gene and when TβRIII 
expression is restored in human breast cancer cells, breast tumor invasion, angiogenesis, 
and metastasis are inhibited in vivo (Dong et. al 2007). Interestingly, the ligands TGFβ2 
as well as inhibin bind this receptor and this could be one of the receptor-ligand 
interactions by which inhibins mediate their growth-like effects on the mammary 
epithelium.  
Activins and inhibins are similar in structure to TGFβ and as such are classified as 
members of the TGFβ superfamily. Activins and inhibins are also the most important 
sub-families of growth factors to consider as they are so well-implicated in differentiation 
as well as proliferation. Activins indirectly enhance the synthesis of follistatin in cultured 
cells from the anterior pituitary (Bilezikjian et al 1993). Activins are also well implicated 
molecularly in inducing apoptosis, immune responses, as well as wound repair (Chen et 
al 2006, Sulyok et al 2004). Interestingly, activins and inhibins have opposing functions 
of one another. Inhibins act to downregulate both the synthesis of and the secretion of 
FSH from the pituitary (Ling et al 1987). Rodent studies have shown that mice treated 
with DMBA develop mammary tumors at a very high rate. As mentioned previously, by 
treating with the pregnancy hormone hCG, the rate of tumorigenesis is greatly reduced, 
and there is a marked increase in the α and β inhibin subunits at the mRNA level as well 
as the protein level in the human breast (Srivastra et al 1999). In addition, multiple 
publications have demonstrated the prevalence of these growth factors in both normal-
adjacent and diseased human breast. Inhibin and activin α, βA, and βB subunits (both at 
the message and protein level) were reported to be present in normal breast tissue 
regardless time during menstrual cycle or menopause (Reis et al 2004). Interestingly, 
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activins and inhibins might very well be the most important growth factors involving the 
ductal outgrowths during pregnancy (Reis et al 2004). Additionally, activin A and its 
endogenous binding protein follistatin are present in human milk during the first week of 
lactation (Reis et al 2004). These families almost certainly have some bearing on 
downstream targets that convey this parity-protective effect in the mammary gland. 
Literature also suggests that members of the Notch family almost certainly play 
some role in the transformation of the mammary gland during pregnancy. Notch is a type 
I transmembrane receptor with multiple epidermal growth factor-like (EGF) repeats. 
Notch is well-known for its ability to affect cell-fate decisions during development. 
Estradiol-induced angiogenesis in MCF-7 breast cancer cells in a 3-D culture is 
completely dependent on Notch signaling (Soares et al 2004). Notch is not only 
implicated on benign developmental processes, but it also has been reported to play an 
indispensable role in cancer though stem cell maintenance. For example, expression of 
the constitutively active intracellular domains of Notch1 or Notch2 protects glioma stem 
cells against radiation (Wang et al 2009). This molecule is indispensable for the crosstalk 
seen between physically adjacent cells in multiple tissues, including the breast.  As Notch 
signaling serves as a means of surveying and maintaining a normal stem cell population  
in the mammary gland, it has great potential to play roles in the protection induced by 
pregnancy. 
 
   Immune Signatures Imparted By Parity 
 One of the criteria of a malignancy is that it must be impervious to the hosts’ 
immune system. If a malignant cell cannot evade the immune system, it would almost 
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immediately be eliminated, and never progress to form advanced disease. It would seem 
likely that molecular players involved in immune surveillance should have a generous 
hand in protecting the early parous breast from cancer. Not surprisingly, several 
important gen
 Complement component (C3), plays an extremely important role in detection and 
elimination of foreign bodies and potentially carcinogenic cell species. Activation of C3 
plays a vital role to the three complement pathways in immunity and results in 
inflammation and elimination of self and non-self targets (Bert et al 2005). C3 was 
reported to be upregulated in the mammary gland of post-menopausal women. This gene 
could represent a way to sensitize the immune system to surveillance and identification of 
potentially carcinogenic cells. Genes such as granulysin are also upregulated in the 
parous breast of post-menopausal women, and granule-mediated cytolysis by CTL and 
NK cells (Balogh et al 2005, Pena et al 1997). Upregulation of granulysin represents a 
way to exploit the lytic functions of immune cells and better sensitize the immune system 
to prohibit the maturation and progression of cancer. Lastly, an important piece of the 
immune system’s protection against cancer should come from a sensing through 
chemotaxis. CCL5 and Interleukin 8 (IL8) were both found to be upregulated 11-fold and 
76-fold in the parous breast, respectively (Russo et al 2007). CCL5 functions to attract T 
helper cells to a site of infection.  IL8 functions as a chemoattractant to neutrophils which 
can then act to further recruit other leukocytes in order to destroy other pre-malignant or 
malignant cells. Immune genes are a vital component of the progression of cancer and 
es with important roles in the immune system have been reported to be 
upregulated in the parous mammary gland. 
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thus are essential to consider when hypothesizing about the protective signature induced 
by pregnancy. 
This project was aimed at further identifying and characterizing the permanent 
molecular fingerprint imparted by parity in the human mammary gland. The literature 
suggests that many of the genes that are significantly changed in response to parity are 
genes involved in immune-surveillance, growth regulation, DNA repair, programmed cell 
death, transcription, and chromatin structure/activators/co-activators (Balogh et al. 2006, 
2007). This characterization is extremely important as it will provide a basis for 
preventative measures as well as novel targets for the development of chemo-protective 
agents against breast cancer. 
 
 
 
Materials and Methods 
Zero Time Human Mammary Tissue 
Women undergoing elective reduction mammoplasties were asked to enroll in our 
study and donate their excised tissue. Immediately following surgery, roughly 70 grams 
of normal breast tissue was procured and dissected under sterile conditions. Tissue was 
then minced, placed in cryogenic vials, and flash frozen in liquid nitrogen. Pieces of 
tissues were also fixed in formalin. RNA was sent out for microarray analyses and 
Quantitative PCR was performed to confirm our results. 
Microarray Analyses 
All microarrays were performed at the University of North Carolina at Chapel 
Hill. Total RNA from Stratagene Universal Human Reference (spiked with 1:1000 with 
MCF-7 RNA and 1:1000 with ME16C RNA to increase expression of breast cancer 
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genes) was amplified and labeled with Cy3 according to Agilent protocols as described in 
Hu et al. (17).  Total RNA from RM was labeled with Cy5. Agilent 4X44K arrays and 
Agilent custom 244K arrays were used (with some reduction mammoplasty (RM), and 
normal adjacent to cancer (CN) patients processed on each format).  Only probes that 
were present on both formats were utilized in the final analysis and intraclass correlation 
coefficients for duplicate experiments conducted on the same platform (range from 0.xx – 
0.xx) did not show meaningful differences from those conducted on different platforms 
(range from 0.xx – 0.xx). Principal components analysis also suggested no substantial 
difference between the two platforms. Duplicate microarrays corresponding to the same 
patient sample were combined by averaging. 
RT and QPCR 
 Total RNA from 50 mg of flash-frozen explants was isolated using TRIzol 
reagent (Invitrogen) standard protocol. Libraries were generated with QSCRIPT (Quanta 
Biosciences) using 100ng of total RNA as a template. Replicates were then diluted 1:10 
for QPCR analysis. Ten independent RT reactions were pooled together to account for 
RT variations, then serially diluted to generate a standard curve. Relative amounts 
(Arbitrary units) of target genes and normalizer genes were determined by plotting the 
critical threshold (ct) values on the standard curve.  
 
Results 
 
 Our final microarray contained 64 loose gene signatures from over 600 genes that 
were altered by parity (figure 2.1). These arrays contained genes that participate in many 
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different biological functions. Examples of these functions include death, proliferation, 
cellular stress, ubiquitin/proteosomal degradation, Wnt signaling, and translation to name 
a few (figure 2.2). NR4A2 functions in cellular survival and was found to be upregulated 
in the parous mammary gland. Conversely, many pro-death genes such as Bax, Caspase 
8, and ApoL6 were downregulated in the parous breast. After generating this heatmap, 
our next step was to verify some of these genes by QPCR. Changes in transcript from 
genes such as apolipoprotein 6 (APOL6), protocadherin 1 (PCDH1), ATPase, class V, 
type 10A (ATP10A), forkhead binding protein 1 (FKBP1), homeobox protein class 9 
(HOXC9), and Caspase 8 were genes that were found to be insignificant when assayed by 
QPCR.  
          Nuclear receptor subfamily 4, group A, member 2 (NR4A2 or Nurr1) was found to 
be significantly upregulated in the parous breast (p=.027; figure 2.3). We then sectioned 
and stained 6 parous and 6 nulliparous patients for Nurr1 based on the significant 
difference seen at the transcriptional level. Nurr1 immunoreactivity was predominately 
found in the ductal epithelium. There was strong NR4A2 immunoreactivity in the stroma, 
and a signal was also seen in the adipose that was proximal to the ducts (Figure 2.4). No 
significant difference in Nurr1 protein could be appreciated between parous and 
nulliparous patient groups. 
           Clusterin (CLU) was also tested by QPCR because it was previously reported by 
Russo to be differentially regulated in response to parity. Our attempts proved 
unsuccessful as a set of reliable primers for either of the two CLU isoforms could not be 
generated. Our next goal was to section and stain 6 parous and 6 nulliparous 0-time 
reduction mammoplasty patients for CLU by IHC. Many tissues of the mammary gland 
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stained intensely for CLU (figure 2.3). CLU stained intensely in the stroma surrounding 
the ducts. In the epithelium, CLU seemed to stain intensely on the luminal border of the 
ducts. There wasn’t any appreciable difference in CLU protein levels between parous and 
nulliparous patients.  
 
Discussion 
 
 There were several deregulated genes included in our heatmap that, based on the 
literature should not be epithelial in origin. These genes are strongly suggestive that our 
array represents additional tissues in addition to the epithelium. Examples of these genes 
include macrophage expressed gene 1, (MPEG1), fibroblast growth factor 1 (FGF1), and 
fatty acid desaturases (FAD1&2). These genes are representative of immune cells, stroma 
and adipose tissues, respectively. Accordingly, we can be fairly confident that our array is 
representative of whole mammary tissue as opposed to just the epithelial component of 
the mammary gland. 
 Almost all of the genes chosen for QPCR verification were determined to be 
statistically insignificant. This is an important in itself because the statistical models had 
to be greatly relaxed in order to generate our parity-induced heatmap. Ultimately, our 
microarray data served as a hypothesis-generating model as to what genes may be 
conveying the parity-protective effect against breast cancer. The insignificance that we 
saw is also indicative that microarray analysis of whole human breast tissue may not be 
the most appropriate scientific method to study transcript levels. Interestingly, several 
genes such as ATP10A and HOXC9 did verify the same trends as the heatmap with an 
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increase in transcript abundance with parity. Although the trends demonstrated by QPCR 
and our heatmap agreed, neither of these genes reached significance.  
Of the many different genes we chose for verification, only one was determined to 
be statistically significant. NR4A2 was suggested by our microarray, and was confirmed 
to be significantly upregulated in the parous breast. NR4A2 is an important gene for 
supporting pro-survival of breast cancer cells, and knockdown of NR4A2 leads to an 
increased rate of anoikis in anchorage independent conditions (Ke et al 2004). Likewise, 
the upregulation of NR4A2 in the parous breast could be a means by which we could 
describe a decreased sensitivity to death. NR4A2 or Nurr1 has also been identified as a 
transcription factor that drives interleukin 8 (IL8) expression. If cells are co-treated with 
the ligand TNF-α, it causes the secretion of IL8 protein (Aherne et al 2009). Vascular 
endothelial cells express both types of IL-8 receptors which play a role in regulating 
tumor and VEC activation which controls proliferation, angiogenesis and metastasis in 
breast cancer (Miller et al. 1998). As previously mentioned, an increased immune 
surveillance partially through the chemoattractant IL8 is a mechanism by which the 
parous breast can identify and eliminate the early stages of tumorigenesis by recruiting 
immune cells to the site of the lesion. We had hoped to see a similar induction of Nurr1 at 
the level of protein by way of IHC. We stained 6 age-matched parous and nulliparous 
patients and did not see any appreciable difference in Nurr1. There didn’t seem to be any 
difference of this protein based on the age of the patient as well.  
Clusterin (CLU) was of interest on our heatmap because it has been reported 
previously to be persistently upregulated in response to parity (Russo et al 2006). 
Interestingly there are two different splice variants of CLU that seem to have different 
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roles. Each one of these transcriptional isoforms differs in their 5’ UTR, however only 
one of these isoforms is translated into a mature form. Intuitively, if CLU is upregulated 
in the protected parous gland it would seem it should function as a tumor suppressor 
gene. The literature tells a different story. CLU has been reported as a viable biomarker 
for stage III ovarian adenocarcinoma, as well as endometrial cancer (Partheen et al 2008). 
Although reports of CLU overexpression in cancer seem unexpected, the functions of this 
protein have still yet to be correctly identified. We would expect the functions of CLU to 
be diverse based on the diffuse staining patterns that were seen in our IHC study. CLU 
has been reported to have functions in cell-cell interactions, apoptosis, protecting fluid-
tissue interactions from stress, transporting lipids just to name a few (Wilson et al 2000). 
More exciting than this eclectic group of functions, is the number of different ligands that 
can bind with this glycoprotein in a tissue-specific manner. CLU has been found 
complexed to apolipoprotein A-I in human plasma, and Glutathione S transferase (GST) 
as well as Complement components (eg C3) in cerebrospinal fluid (Ghizo et al 1990, 
1993).  CLU could possibly be acting to sequester and dispose of excess ligands in 
metabolically overactive tumor environment, and is ultimately acting to reduce stress to 
the surrounding tissues.  
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 Forward Reverse 
18SrRNA GGA GAG GGA GCC TGA GAA AC TCG GGA GTG GGT AAT TTG C 
CK14 TTC TCC TCT GGA TCG CAG TC ATG ACC TTG GTG CGG ATT T 
         CK18 CAC AGT CTG CTG AGG TTG GA GAG CTG CTC CAT CTG TAG 
GG 
RPS3 GCA AGA TGG CAG TGC AAA TA ACT CAT TCA GTT CAG CTT 
TGA AGA 
ERCC2 GGC CTC CTG GTA TGA GCA CCT GGG TCT CAA TAA AGA 
GCA 
CASP8 TAG GGG ACT CGG AGA CTG C TTT CTG CTG AAG TCC ATC 
TTT TT 
SNIP1 GAG CCC GAG GAG TTA GCC TCT TAC TGC GAG GAG ACT 
TGC 
APOL6 AGT GAG GCT GGT GTT GGT TT CGT CTT GTA GCT CCA CGT 
CTT 
EN1 CAT GGC CCA GGG ACT GTA CTC GCT CTC GTC TTT GTC CT 
ATP10A GGA GGT CAT CAC CCT GAA TG GCA TAG GCA CTG GTC TAG 
CA 
TGFBII CCA AAG GGT ACA ATG CCA AC CAG ATG CTT CTG GAT TTA 
TGG TAT T 
CXCL9 CCT TAA ACA ATT TGC CCC AAG TTG AAC TCC ATT CTT CAG 
TGT AGC 
TRIAD 3 TCC TCA GCA GCA TGA AGA AG TCG TGA TCT CTG AGG TTT 
ATT TGT 
FADD CAG AGC CCA TGC TCA ACC ACA TCC TTT CTG CCA ACT GC 
TNFRSF10c CCC TAA AGT TCG TCG TCG TC TGG TGG CAG AGT AAG CTA 
GGA 
NR4A2 TGA AGA GAG ACG CGG AGA AC AAA GCA ATG GGG AGT CCA G 
TGFBRIII GAT TTC ATC TTC GGC TTG AAA GCT CAG GAG GAA TAG TGT 
GGA 
GPX2 GTC CTT GGC TTC CCT TGC TGT TCA GGA TCT CCT CAT 
TCT G 
P53 AIP1 AGG GAG CAG GAG CTG GAT GGA CTG CTG CTT CTT TGG TC 
ARIIA AAA GCC CAG TTG CTT AAC GA TGC CAT GAC TGT TTG TCC TG 
TK1 CGT CGA TGC CTA TGA CAG C CAG CTT CTG CAC ACA TGA 
CC 
TRAF 5 TTC AAG CAG TTT GCA CAG TTG AAT GTG ACT CCG AAA AAC 
CTG 
TRAF 7 CCA GCA CCC TTG CCT ACT C GGA CAG AGA TGG CGG A 
PCDH7 CTA CCA CCA GCC AAC ACA TTT TGT ATG GAT GTA GAC GCA 
TCT GT 
AICDA GAC TTT GGT TAT CTT CGC AAT 
AAG 
AGG TCC CAG TCC GAG ATG 
TA 
HOXC9 GCA GCA AGC ACA AAG AGG A CGT CTG GTA CTT GGT GTA 
GGG 
FKBP1A CTC TAG GGG TTG CAC TCT GG CTG GGA GGA GAT TGA ACC T 
TGIF TGG GAT CAG AGC GTC CTG TT CCG GAC CTC AAC CAG GAC 
TT 
 
 
 
 
 
 Table 2.1 – Primer sequences used for QPCR assays (Continued on next page)                                                                                                       
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XRCC6 AGA GTG AAG ATG AGT TGA 
CAC CTT T 
CCA AGA GAT CTC GAT CAC 
TGC T 
PARP1 TCT TTG ATG TGG AAA GTA TGA 
AGA A 
GGC ATC TTC TGA AGG TCG 
AT 
ERCC1  GAA ATT TGT GAT ACC CCT CGA 
C 
GAT CGG AAT AAG GGC TTG G 
XRCC2 GCC TGT CAG CTT TTT ACT GGA 
T 
CCT CAG AGT AGA CTC CTG 
TAA GTT CA 
RAD23B CCC TGA CAG AGC AGT GGA GT GGT CAA CCA CAG CCT GAC 
TT 
ERCC6  AAG ATT ATT ATA AGC AGC GGT 
TAA GG 
GCA TCA CTT TCC TCA GAA 
TCG 
ERCC 8 ACA CAT GTA AAG CAG TGT GTT 
CC 
CAC ACT GTA TCT GTG AAC 
ATC AGG 
TRADD  CAG AAG GTG GCA GTG TAC 
AGG 
CAG CAT CTG CAG CAC GTC 
P53TG1 GGG CTG AGG ACC CAA AGT TCA TTC TTC TCC CTG CGA GT 
BAX alpha CAA GAC CAG GGT GGT TGG CAC TCC CGC CAC AAA GAT 
PABC4 CTT TTG GAT CAA TTA CCA GTG 
CT 
AGC CAA ACC CTT TGC TTC TT 
SFRS2 TTG GCC AGT ATT GCA GAT TTT CAA TAC ACG CCC ACA GAA 
AC 
SNRPB CTG GAA GAG GGA CTC CAA TG GGG CCA AGA TGA GTC TAG 
GG 
MED18 GAT ATA ATT CCC GGC TTC TCG GTC AGG TAA GGC ACG GGA 
TA 
PAQR3 ACA TGA GGA TTT GGG AAC 
AGA 
TCC GAG GTA GTT TAG TTG 
TCC AG 
RNF41  TGC CCT ATT TGC AGT GGA GT CGT TGC AGA AAG CAT GTT 
CA 
QK1 AAC TTC TGC GGG ATC TTC AA TGT CTT TCC GTA CTC TGC 
TAA TTT C 
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Figure 2.1- Heatmap from microarray suggesting differentially regulated genes in 
0-time reduction mammoplasties. Green bar above denotes parous, while red 
denotes  nulliparous patients. Red symbols denote upregulation, while green 
denotes downregulation. 
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Figure 2.2 – QPCR data depicting various transcript levels isolated from 0-time 
reduction mammoplasty specimens. Genes were chosen in order to confirm 
signature produced by microarray. (* denotes statistical significance) 
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Figure 2.3 - T=0 reduction 
mammoplasty specimens were stained 
for Clusterin IHC. Staining 
predominately was found on the luminal 
border of most ducts. There was also a 
strong stromal signal found in most 
patients. There was no appreciable 
difference in intensities between 
nulliparous and parous patients as 
suggested at the level of transcript by the 
microarray. 
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Figure 2.4 – Photomicrographs showing T=0 reduction mammoplasty specimens 
stained for NR4A2 (Nurr1) IHC. Both luminal and basal epithelial cells showed Nurr1 
immunoreactivity. Nurr1 showed localization in bothe the nucleus and cytoplasm. 
Stromal cells surrounding the ducts also showed some immunoreactivity. There was 
no appreciable difference in Nurr1 intensity between parous and nulliparous patients. 
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CHAPTER 3 
DIFFERENTIAL SENSITIVITY TO IR-INDUCED APOPTOTIC DEATH IN 
THE PAROUS BREAST  
 
Introduction
We hypothesized that the parous mammary gland would have a greater sensitivity 
to IR-induced apoptotic death. Our hypothesis was based on the fact that irradiated 
parous mice show a persistent increase in sensitivity to apoptosis, as well as nuclear p53 
accumulation when compared with age-matched nulliparous mice. This increased 
sensitivity to death is also comparable to Estrogen and Progesterone- treated nulliparous 
mice (Dunphy et. al 2008). Our first goal was to assay the sensitivity of the human 
mammary gland to programmed cell death by first quantifying apoptosis by way of 
TUNEL assay. Secondly, we wanted to correlate the molecular players conveying this 
putative sensitivity by doing a high-throughput micro-array analysis, and QPCR to verify 
microarray analysis. We reasoned that if the mammary gland is more sensitive to death 
after a carcinogenic event then it would be unable to further progress and mature into a 
cancer. Likewise, the genes we expected to see differentially regulated in response to IR, 
should be those previously characterized to be differentially expressed in the parous 
breast involved in cell death, and apoptosis. 
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Apoptotic Pathways  
 Apoptosis and other forms of cell death are of great importance in describing 
models of how cancer arises and progresses. Accordingly, it was also important in our 
study to consider genes downstream from the previously mentioned DDR that are 
involved in apoptosis. Apoptosis can arise from two separate courses: it can be induced 
extrinsically through cell surface receptors or intrinsically from the mitochondria.  
There are vast arrays of extrinsic cues that can induce programmed cell death. 
Such cues include hormones, cytokines, toxins, or nitric oxide (Popov et al 2002, Brun et 
al. 2003). Perhaps one of the most widely studied pathways involving programmed cell 
death involves the second mitochondrial activator of caspases (SMACs) which are 
released into the cytosol after an increase in the permeability of the mitochondrial 
membrane. SMACs then bind the antagonists- inhibitors of  apoptosis proteins (IAPs).  
By binding the inhibitors, SMACs deactivate IAPs and the signal is transduced with the 
proteolytic activation of caspases which eventually cause cleavage of genomic DNA. We 
know that execution of apoptosis relies on the cleavage of Bcl-2 member Bid by caspase 
8, which subsequently releases pro-apoptotic factors from the mitochondria, and drives 
apoptosis (McDonnell et al. 1998). 
There are two different mechnanisms by which apoptosis can be induced from 
cell surfaces. One model involves the induction by the ligand tumor necrosis factor 
(TNF). The second mechanism involves the Fas-Fas ligand-mediated model. Both the 
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TNF and the fas-fas ligand-mediated models involve receptors of the TNF receptor 
(TNFR) family which are specifically activated by extrinsic signals (Wajant et al 2002). 
Although the pathways described are extremely abridged, the differential 
regulation of these death pathways can allow the cells comprising the mammary gland to 
show differential and flexible responses to extrinsic signals. Likewise, the genes 
encoding the players involved in programmed cell death represent an indispensible class 
of genes to consider when identifying mechanisms for a parity-induced sensitivity to IR-
stimulated death. 
 
 
Role of p53 in Apoptosis 
P53 is well supported in the literature as the affector that cues the apoptotic 
response to DNA damage. Medina et. al demonstrated that mice primed with the sex 
steroid hormones estrogen and progesterone (E+P), and then challenged with chemical 
carcinogen methylnitrosourea (MNU) show nuclear accumulation of p53 (Medina et al 
2002), an observation not seen in mice that were not primed with hormones (Medina et al 
2000). Medina and Kittrell then demonstrated that p53 function was required for 
hormone-mediated protection of mouse mammary tumorigenesis in response to DMBA 
(7,12-Dimethyl-benz[a] Anthracene), and the absence of p53 abrogated a significant 
portion of the protective effect exerted by short-term hormonal stimulation (Medina et al 
2000, 2003). Taken together, these results suggest that p53 responsiveness is persistently 
altered by hormonal stimulation of the virgin mouse mammary gland, and that p53 
promotes cell cycle arrest and apoptosis in response to DNA damage. 
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 As mentioned previously, p53 is at a direct interface with the DDR as it is directly 
activated by ATM. P53 is considered a tumor suppressor because of its ability to cause 
transcription of many pro-apoptotic genes. p53 activates genes such as Bax, PIG3, 
PUMA, Noxa, P53AIP. Interestingly, many of these same genes involved in cell-death 
pathways have been shown to be upregulated in post-involuted rat mammary glands. 
Several studies show this parity-induced fingerprint is characterized by an elevated 
expression pro-apoptotic genes such as testosterone-repressed prostate message 2 
(TRPM2), interleukin 1β-converting enzyme ICE),  p53, p21, and c-myc. Bax was found 
to be signficantly upregulated in the mammary gland of post-menopausal parous women 
(Balogh et al 2007). Also, it was shown that upregulation of the pro-apoptotic gene bcl-
XS was found to be upregulated in mammary glands of rats (Russo et al 2006).  
 These death-related pathways were vital in forming our hypothesis. If a 
premalignant cell is induced to undergo apoptosis then it would never progress to form 
advanced disease.  Similarly the many pathways and innumerable genes comprising these 
death pathways represent a reservoir of potential molecular candidates conveying the 
long-term protection against breast cancer seen in early-parous women. By increasing the 
transcription and production of these pro-death molecules through promoter alterations, 
the parous breast could shift the axis to a mammary gland with a propensity towards 
stress-induced death. 
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Materials and Methods 
Human Explants 
Women undergoing elective reduction mammoplasties were asked to enroll in our 
study and donate their excised tissue. Immediately following surgery, roughly 70 grams 
of normal breast tissue was procured and dissected under sterile conditions. Small 
portions (roughly 200mg), of stromal/epithelial tissue were grossly dissected from the 
surrounding adipose tissue, placed on a small piece of surgical foam, and cultured in 
phenol-free basal medium for 24 hours at 5% CO2 to allow for equilibration. The tissue 
culture was then exposed to 5Gy of ionizing radiation while a duplicate organ culture was 
left unirradiated as a control. The tissue was left in culture for the subsequent six hours to 
allow for uninterrupted changes in gene expression. Finally, the replicate tissues were 
fixed in formalin and flash frozen in liquid Nitrogen for immunohistochemical analysis 
and RNA isolation, respectively. RNA was sent out for microarray analyses and 
Quantitative PCR was performed to confirm our results. 
 
Microarray 
RNA was isolated from whole mammary tissue using Qiagen Minikit according 
to manufacturer’s instructions. RNA was then eluted from the column with NFH20, 
measured with a spectrophotometer, and sent to the Genomics Core University of North 
Carolina, Chapel Hill under the care of Dr. Melissa Troester where it was reverse 
transcribed and subject to microarray analysis. 
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RT and QPCR 
Total RNA from 50 mg of flash-frozen explants was isolated using TRIzol 
reagent (Invitrogen) standard protocol. Libraries were generated with QSCRIPT (Quanta 
Biosciences) using 100ng of total RNA as a template. Replicates were then diluted 1:10 
for QPCR analysis. Ten independent RT reactions were pooled together to account for 
variation in RT reaction, then serially diluted to generate a standard curve. Relative 
amounts of target genes and normalizer genes were determined by plotting the critical 
threshold (ct) values on their respective standard curve. To account for changes in a 
particular gene, the normalized levels from the unirradiated explant cDNA (control) was 
subtracted from the irradiated explant cDNA for each respective patient. 
TUNEL 
Four µm sections of mammary tissue were deparaffinized in xylene, rehydrated in 
graded ethanol, and subjected to terminal deoxynucleotidyl transferase dUTP nick-end 
labeling (TUNEL) of apoptotic DNA using the TACS XL Blue Label Kit (Trevigen). A 
minimum of 2,000 mammary luminal epithelial cells were counted. Percent positive cells 
were calculated by taking the ratio of positive cells over total cells counted for each 
sample.Percent positive cells were calculated by taking the ratio of positive cells over 
total cells counted for each sample. 
Statistical Analysis 
All statistical calculations were performed using GraphPad Prism Version 6. 
Comparisons between groups were carried out using a Student’s pair-wise t-test 
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Results 
         Terminal deoxynucleotidyl transferase dUTP nick-end labeling (TUNEL) of 
apoptotic DNA was performed on paraffin embedded organ cultures. Nulliparous patients 
had significantly more apoptotic epithelial cells (Mean = 2.683) than their parous cohorts 
(Mean = .5809) 6 hours after irraditation. Parous patients also tended to cluster much 
closer together (SD=.61%), whereas nulliparous patients had much more diffuse levels of 
staining (SD=1.386). This data suggests that the nulliparous breast is more susceptible to 
IR-induced apoptosis. 
   Our first micro-array analysis revealed a loose 200-gene signature which showed 
differential transcriptional responses between parous and nulliparous women in response 
to radiation. Breast tissue harvested from nulliparous women showed the most striking 
changes with an increased expression of 80% of genes in response to radiation whereas 
tissue from parous women showed no change or decreased expression of these same 
genes. The other 20% of signature genes were strongly down-regulated in tissue from 
nulliparous women in response to radiation, while they were up-regulated or remained 
unchanged in parous tissue. Genes that regulate the ubiquitin/proteosome, cellular stress, 
and Wnt pathways all were differentially regulated between parous and nulliparous 
patient groups. Many other genes involved in vital cellular processes such as 
transcription, translation, cytotaxis, and death were differentially regulated in response to 
parity (Table 3.1).  
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We chose to first focus our efforts on the death pathways suggested by our 
microarray to be altered by parity. Table 3.1 suggests the pro-apoptotic Tumor Necrosis 
Factor (TNF), pathway to be a viable candidate. Immediately, our signature shows three 
key genes in this pathway. The downregulation of the TNF-α decoy receptor 
TNFRSF10C, the downregulation of the TNF-α Receptor Associated Factor gene TRAF 
5, and the upregulation of TRAF7 in parous mammary tissue are all important 
observations. TNFRSF10C was shown to be downregulated in the parous breast in 
response to (figure 3.1).  QPCR was performed and TNFRSF10C was found to be 
significantly upregulated in the nulliparous breast, while the converse downregulation 
was found in the parous breast (P=.0031; Figure 3.9). QPCR data for TRAF 5 and TRAF 
7 demonstrated no significant difference between parous and nulliparous glands (Figure 
3.9). We tested TRAIP, TRIAD3, FADD, and TRADD (Figure 3.9) - several genes 
involved in TNF death pathway to see if there was differential expression between parous 
and nulliparous women. QPCR analysis showed that there was no significant difference 
in expression levels between parous and nulliparous patients after irradiation. 
We focused our efforts on confirming genes involved in growth and cell-signaling 
which were suggested by our microarray data by QPCR analysis.  The microarray 
suggested several genes involved in the TGFβ signaling pathway. The heatmap from the 
first microarray suggests that activin receptor type IIA (ARIIA) was downregulated in the 
parous breast in response to IR (Figure 3.1).  Although this didn’t seem to be a 
statistically significant difference from the microarray, we aimed to confirm this trend by 
QPCR. We were able to find a set of primers that produced a an acceptable standard 
curve with a 1:4 cDNA dilution series. Many of our samples (diluted 1:10) showed little 
31 
 
or no expression in any of our assays. cDNAs were remade and diluted 1:5 in order to 
determine whether loading a more concentrated template would produce a functional 
assay. This strategy did not prove to be effective as these same wells did not amplify. Our 
first microarray also suggested the TGFβ family-related gene- smad nuclear interacting 
protein 1 (SNIP1), however our explants seemed to have statistically insignificant 
differences in this gene as determined by QPCR (Figure 3.11). Several other genes such 
as transforming growth factor β receptor III (TβRIII) and NotchII did confirm with 
statistical significance (Figure 3.8, 3.10). We wanted to see if our observed 
downregulation of TβRIII message had a corresponding downregulation of TβRIII 
protein. IHC was performed on paraffin embedded explants from 3 parous and 3 
nulliparous patients. The myoepithelial cells of the mammary gland stained intensely for 
TβRIII protein (Figure 3.6). Although two of the nulliparous patients followed our 
expected trend in response to IR, one did not; the parous patients didn’t have any 
appreciable change in intensity in response to IR. This preliminary data is important 
because it suggests that the corresponding decrease in TβRIII protein might be a 
significant finding. As of now we could only speculate with an n of 3 in each group.  
Notch II was also suggested by the heatmap from our first microarray. According 
to the array, there was a negligible change in transcription in response to IR. Conversely, 
in nulliparous women there was a slight increase in Notch II transcript in response to IR. 
We attempted to verify these results by QPCR, with 6 parous and 6 nulliparous patients 
(Figure 3.10). We were able to repeat the trend that was seen in the microarray with 
statistical significance (P=.05). Two of the nulliparous patients seemed to have extremely 
low levels of this transcript, (ie amplification after 37 cycles of PCR). These patients 
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were excluded from the analysis based on the appearance of the melt-curve.  
 Our first microarray suggested that the gene- splicing factor, arginine/serine-rich 
2 (SFRS2) was downregulated in the parous explants in response to radiation. This 
particular gene was of interest because splicing factors can have widespread effects on 
multiple genes by differentially splicing mRNAs. We attempted to confirm SFRS2 by 
QPCR and our results suggested that the differences between parous and nulliparous 
patients at the transcript level were statistically insignificant. 
Interestingly, several phase-two detoxifying enzymes were also found to be 
upregulated in the parous breast in response to IR. QPCR Primers were designed for 
NOXA, and glutathione peroxidase 2 (GPX2). We never developed a working assay for 
NOXA because of the low abundance of the transcript in our standards as well as our 
patient cDNAs. Basal levels of GPX2 on the other hand, were found to be significantly 
upregulated in the parous breast prior to IR (Figure 3.13). Changes in GPX2 in response 
to irradiation were found to be insignificant when comparing parous versus nulliparous 
groups. 
 For our second microarray analysis, we sent out RNA from fifteen additional 
patients. Many of the genes from our initial 200 gene signature were eliminated with a 
larger number of patients included. Likewise we were left with a 21 gene signature that 
confirmed for all 30 patients. This second heatmap (figure 3.2) represents a much more 
stringent fingerprint with a reduced number of genes that are differentially regulated in 
response to irradiation between parous and nulliparous patient sets. 
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Discussion  
TUNEL analysis revealed a surprising decrease in apoptotic death in parous 
patients at our six hour timepoint. This result seemed counterintuitive given on what is 
reported in the literature, with an increased incidence of apoptotic death in the mammary 
gland of the parous rodents. Unlike the BALB/c animal model, the effects of parity on 
human breast tissue appears to favor the increase DNA damage response over the 
apoptotic response under our culture conditions. Furthermore it doesn’t seem as though 
p53 plays as pivotal a role in our model as described in the mouse. In a previous project, 
67 patients were stained for p53 by IHC. After extensive analysis and blinded scoring by 
two pathologists, the immunoreactivity was found to be an insignificant difference 
between parous and nulliparous groups. Lastly, the p53 target gene (p53TG1) levels were 
measured by QPCR as it has been reported to be persistently downregulated in the post-
menopausal parous mammary gland. P53TG1 did not show any significant change in 
response to radiation (p=.7767). We can say fairly confidently that p53 isn’t differentially 
regulated in our system, at the 6 hour timepoint. This does not exclude the possibility that 
there might be differences in the length of time that p53 stays active between these 
populations, but it does rule out a comparable change in p53 sensitivity as is observed in 
the rodent model. This discrepancy between mouse and human models is an important 
observation because is suggests there may be different mechanisms conveying this parity-
protective effect between species. 
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The pro-apoptotic BAX was chosen as a viable candidate conveying this 
increased sensitivity to death seen in the nulliparous group for the reason that it was 
reported to be expressed at 2.7 fold higher levels in the post-menopausal parous breast 
(Russo et al 2008). Bax is also reported to be activated in response to IR directly through 
Rac1 activation by p38 (Kim et al 2008). Although an increased expression of BAX 
wasn’t seen in our nulliparous explants, there were significantly higher basal levels of 
BAX transcript in unirradiated nulliparous explants. p38 transcript levels were also found 
to be significantly upregulated in the parous breast in response to IR, which suggests that 
the upregulation of this gene is driving a cytoprotective pathway. Interestingly, p38 
MAPK has also been reported to regulate chromatin remodeling as well as DDB2 
degradation for facilitating assembly of the molecular players comprising the NER 
pathway (Zhao Q et al 2008). This data suggests that while the nulliparous breast may in 
fact have a higher sensitivity to death, the epithelium comprising the parous breast has a 
propensity of rescuing damaged cells via the DDR.  
As mentioned earlier, NR4A2 expression has been shown to impart a pro-survival 
phenotype of breast cancer cells by preventing anoikis (Ke et al 2004). Likewise, it was 
shown that NR4A2 promotes the survival of neurons in the CNS. We showed that 
NR4A2 was significantly upregulated in our parous T=0 reduction tissues both with our 
microarray as well as QPCR. This could partially account for why we are seeing less 
death in the parous tissue, as this upregulated pro-survival gene is saving the epithelium 
from apoptosis.  
We next shifted our focus further downstream of the DDR pathway to pathways 
involved in cell death. We looked at many members of the TNF α superfamily and none 
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were found to be significantly deregulated in response to IR in parous patients. One of the 
genes we tested from this pathway did confirm with significance, however. TNFRSF10c 
is well reported in the literature as a tumor suppressor gene. In fact, 8p21.3 is the locus 
where this gene is found which happens to be the most frequently deleted locus in human 
prostate cancer. Many reports have also shown promoter methylation upstream of 
TNFRSF10c (Cheng et al 2008). This gene encodes a receptor that contains an 
extracellular TRAIL-binding domain and a transmembrane domain, but no cytoplasmic 
death domain. Ultimately, this receptor acts to dampen the pro-death signal conveyed by 
the TNF molecule. This result would have a dominant-negative effect on the pathway, as 
it was found to be significantly downregulated in the parous breast in response to IR. We 
reasoned by way of our original hypothesis that if the parous breast is more sensitive to 
IR induced death, then we would like to see a downregulation of this gene. If there were 
less of this negative receptor being made, then the transduction of the pro-death pathway 
should propagate more efficiently in the presence of TNF ligand.  
There was another member an apoptotic pathway suggested by the literature to be 
persistently upregulated in the post-menopausal parous mammary gland (Russo 2008). 
Bcl2- associated factor x (BAX) was found to be significantly downregulated in the 
parous breast prior to irradiation. The BAX transcript level showed a very small 
upregulation to IR at our six hour post-IR timepoint. Conversely, in the nulliparous breast 
there seemed to be an upregulation in this pro-apoptotic transcript 6 hours post-IR (figure 
3.11). We next looked at the BAX levels in our 0-time reduction tissues. Contrary to what 
we saw in our explants, it seemed as though the levels tended to be slightly upregulated 
in the 0-time, noncultured tissues.  
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Transforming growth factor-beta (TGF-β) is a multifunctional family of cytokines 
that regulates tissue development as well as repair processes. Type III TGF-β receptor 
(TβRIII) is downregulated in a wide range of human cancers, including breast cancer. 
TβRIII is further supported in the literature as a bona fide tumor suppressor gene because 
when TβRIII expression is restored in human breast cancer cells, breast tumor invasion, 
angiogenesis, and metastasis are inhibited in vivo (Dong et. al 2007). The data obtained 
from the microarray indicated that TβRIII is downregulated in nulliparous women in 
response to radiation, whereas there was little to no change in the parous group (Figure 
3.1). Our group was able to replicate the microarray data by choosing a myoepithelial-
specific cytokeratin -CK14. Although the nulliparous values are more diffuse (SD= .95) a 
number of the values decrease with radiation. The TβRIII levels in parous patients 
clustered much closer together (SD = .27), suggesting a similarity within the 
experimental group, and they don’t appear to be responsive to radiation (Figure 3.8).  
           We wanted to see if our observed downregulation of TβRIII message had a 
corresponding downregulation of TβRIII protein. IHC was performed on paraffin 
embedded explants from 3 parous and 3 nulliparous patients. The myoepithelial cells of 
the mammary gland stained intensely for TβRIII protein (Figure 3.6). Although two of 
the nulliparous patients followed our expected trend, one did not; the parous patients 
didn’t have any appreciable change in intensity in response to IR. This preliminary data is 
important because it suggests that the corresponding decrease in TβRIII protein might be 
a real. As of now we could only speculate with an n of 3 in each group.  
 Several other important cytokines were also shown to be differentially regulated 
in response to IR in the parous breast. For instance mitogen activated protein kinase 14 
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MAPK14 (aka p38) was shown to be significantly upregulated in the parous breast in 
response to IR. It becomes hard to speculate what role this increase of p38 message might 
have physiologically because it might not correspond to an increase in protein. To rule 
this out we stained our explants for p38 via IHC. This gene was unequivocally IR-
inducible, however there was very little staining seen at our 6 hour timepoint. Based on 
evidence in the literature, we decided to stain our sections at half and one-hour post IR. A 
majority of the specimens stained the most intense at our earlier, half-hour timepoint. 
Although this experiment was useful to determine the timepoint at which to see robust 
increase in p38 protein, it didn’t help to explain the significant parous upregulation in 
transcript at 6 hours after irradiation. It’s also important to consider that p38 induction 
can occur in a biphasic manner. It’s been reported that p38 activity indeed does have 
biphasic properties with the first peak occurring at 1 hour, and the second peak occurring 
between 6 and 8 hours (Van Wagoner 2000). We also tried spiking a p38 inhibitor onto 
one parous and one nulliparous explant and staining those tissues for TUNEL to see if we 
could rescue the observed sensitivity to apoptosis that we had seen earlier. The two 
explants did have similar levels of TUNEL staining when treated with the inhibitor. 
 The gene GADD45A was chosen for QPCR analysis as it is activated in response 
to IR. The GADD45A protein responds to IR and other environmental stresses by 
activating the p38/JNK pathway via MTK1/MEKK4 kinase (Bulavin et al 2003). 
Likewise, we reasoned that this gene could be used to explain the differential regulation 
of p38 transcript between parous and nulliparous patients.  The GADD45A activation of 
the p38 pathway results in cell cycle arrest through activation of p53 (Bulavin et al 2003). 
Most of our explants showed an upregulation in GADD45A transcript six hours after 
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irradiation.  There didn’t seem to be a significant deregulation between parous and 
nulliparous patient groups, however. Basal levels of this transcript were comparable of 
between parous and nulliparous groups as well. It could very well be that we weren’t 
examining the correct timepoint for this gene. It would be interesting to stain our explants 
for GADD45a IHC at different timepoints to see when the maximal levels of this protein 
occur after irradiation. We could also stain for players further downstream of GADD45a, 
but upstream of p38. One such protein could be phosphorylated MEKK4 because this 
would be more indicative of activity, suggesting a timepoint at which the pathway is 
physiologically active. 
The microarray produced from our explant culture had differential regulation of 
several genes involved in the phase II detoxification system. The mammary tissues were 
still somewhat metabolically active and they were likely producing reactive oxygen 
species (ROS). ROS have long been characterized to be DNA damaging agents. Many of 
the GPX Enzymes in the phase II detoxification process are involved in degradation of 
these chemicals. GPX2 can also act to suppress COX-2 expression and PGE2 production, 
which explains its potential to inhibit migration and invasion of cultured cancer cells 
(Brigelius-Flohé et al 2009). It was exciting to see this gene significantly upregulated in 
the parous breast. This suggests that the parous breast is better equipped to degrade 
DNA-damaging peroxides than the nulliparous breast. It is plausible that the early-parous 
patient is less-likely to develop cancer because of the decreased likelihood of DNA 
damage from peroxides. By upregulating the genes involved in the catabolism of these 
chemicals, it further decreases the chance for a carcinogenic event. 
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Figure 3.1- Heatmap generated from first microarray. Heatmap suggests 
roughly 200 genes differentially regulated in response to IR. Green 
represents an upregulation, and red represents a downregulation. Values 
were generated by subtracting unirradiated explants, from irradiated. 
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Death Proliferation 
Stress 
Pathway Ubiquitin/Proteosome 
Wnt 
Related Translation 
AKT1S1 Profilin FKBP52 RPN1 Profilin EIF4A1 
FADD Csk SGSTM4 ADRM1 Fli-1 EIF5A 
HuR Spred SGTA Trim25 IER3 EIF2S2 
TRAF7 E2F4 TXNRD2 NOB1P Wnt5a EIF4G1 
p53 IG5 DUSP16 UBE2M FzD10   
ASNA1 Pbx1 Cyp2B6 UBE2Q LRRFIP   
PPP4C RNF3 Cyp2A6 PSM013     
PRKAG1 ZBTB20 Cyp2A13 SUMO3     
IER3 Cyclin G2 Cyp4x1 IER3     
TNFRSF10C PDGFa CypB561b1 DUB3     
TRAF5 
Metallothionein 
3 
 
Elk3       
PIM2 ErbB4         
SAV1           
Table 3.1- Summary and coarse grouping of signature genes shown by microarray. Red 
text indicates a downregulation in that particular gene in parous patients, green vice versa. 
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Figure 3.2- Heatmap generated from second microarray. Heatmap suggests 21 genes 
differentially regulated in response to IR. Many of the original 200 genes fell off the 
original list when we increased the number of patients for analysis. Green represents 
an upregulation, and red represents a downregulation. Values were generated by 
subtracting unirradiated explants, from irradiated. 
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Figure 3.3 – Photomicrographs from TUNEL assay and graphs from corresponding 
data. Data suggests a decreased incidence of apoptosis in parous patients. Bar graph 
and scatterplot were generated from the same values. P=.0023 
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Figure 3.4 – p21 staining showing 
immunoreactivity exclusively in the 
nucleus of predominately luminal, but 
some myoepithelial cells. 6 aged 
matched parous and nulliparous women 
were scored for percent positive cells 
and intensities were noted. No 
significant difference was seen between 
parous and nulliparous patients. 
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Figure 3.5 – Photomicrographs from p38 (MAPK14) IHC stained, paraffin embedded 
explants. P38 was unequivocally induced by IR. Most patients showed the greatest 
amount of p38 immunoreactivity 60 minutes after irradiation. P38 stained 
predominately in the nuclei of luminal epithelium. There was no appreciable 
difference in p38 levels when comparing parous to nulliparous patients. 
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Figure 3.6 – Photomicrographs from TβRIII(Betaglycan) stained paraffin embedded 
explants. TβRIII stained most intensely in myoepithelium. Signal seemed to be 
localized in both the cytoplasm as well as the cell membrane. Several epithelial cells 
showed  some nuclear localization although this is a membrane-bound receptor, as 
seen in panel on lower right. 
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Figure 3.7 – Photomicrographs showing IHC staining for ELAVL1 (Hurr) on paraffin 
embedded explants. NR4A2 stained the most intensely in the epithelium of ducts. 
There was signal seen in both the cytoplasm, as well as the nuclei. There was no 
appreciable difference seen between parous and nulliparous groups 
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Figure 3.8 – QPCR data from explants depicting basal levels as well as changes 
in transcripts in response to irradiation. Genes were chosen in order to confirm 
signature produced by microarray. (* denotes statistical significance) 
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Figure 3.9 – QPCR data showing changes in expression of genes involved in the 
TNF pathway after irradiation. TNFRSF10C was chosen in order to confirm that it 
was differentially regulated in response to IR. ** denotes a significant change in 
between parous and nulliparous sets. 
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Figure 3.10 – QPCR data from explants depicting changes in expression  
in response to irradiation. Genes were chosen in order to confirm signature 
produced by microarray. (* denotes statistical significance) 
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Figure 3.11 – QPCR data from explants depicting basal levels as well as 
changes in transcripts in response to irradiation. Genes include the pro-
apoptotic BAX. Lowermost scatterplot suggests slightly higher levels of BAX 
in the parous 0-time reduction mammoplasties. The opposite trend was seen in 
basal BAX levels in explants. (* denotes statistical significance) 
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Figure 3.12 – QPCR data generated 
from explants in response to IR 
MAPK14 (p38) transcript levels. 
MAPK14 was chosen as it was 
suggested to be differentially 
regulated by our microarray. Minor 
increases of p53TG1 transcript 
suggests that the p53 is not the 
major stress pathway at 6 hours 
post-IR in our system. (* denotes 
statistical significance 
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Figure 3.13 – QPCR data showing increased levels of phase-2 detoxifying 
enzyme GPX2 in the parous explants. There was no different change seen in 
expression between parous and nulliparous patients after irradiation. GPX2 
was suggested to be differentially regulated by our microarray. (* denotes 
statistical significance. 
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Figure 3.14 – QPCR data showing expression levels of GADD45A. 
GADD45A was chosen as it is induced by IR and is at interface with MAPK14 
signaling pathway. No appreciable difference in expression was seen between 
parous and nulliparous patients. 
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Figure 3.15 – QPCR data showing slightly increased levels of the p53 responsive 
genes- P53AIP and MDM2 in irradiated parous explants. Neither of these genes 
were found to be statistically significant. 
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CHAPTER 4 
INCREASE IN NUCLEOTIDE EXCISION REPAIR (NER) PATHWAY IN 
RESPONSE TO IONIZING RADIATION IN THE PAROUS BREAST 
 
Introduction  
DNA Damage Repair (DDR) Pathway  
 
The DNA Damage Response (DDR) is the furthest upstream system to consider in 
response to DNA breaks. Having a firm understanding on how cells comprising the 
mammary gland senses and responds to DNA damage is instrumental to identifying 
specific molecular players that convey a parity-induced protective effect. As mentioned 
previously, IR is characterized by its ability to cause double-stranded DNA breaks 
(DSBs). There are two major types of DSB repair pathways – homologous recombination 
repair (HRR) and nonhomologous end-joining (NHEJ). The framework of what we know 
about how the cell senses and reacts to a compromised genome has come from primarily 
from yeast studies. One of the first and best characterized pathways involving the DDR is 
a pathway involving the serine/threonine kinase Ataxia telangiectasia mutated (ATM). 
This classic pathway was first characterized in response to IR. ATM was shown to 
phosphorylate and activate the tumor suppressor p53 which then can cause apoptosis. 
ATM is also the major kinase that phosphorylates H2AX in response to double strand 
breaks (Burma et al. 2001). BRCA2 is reported to associate with the RAD51 protein, and 
this complex acts to load RPA proteins which signal to a variety of other downstream 
molecules and the repair process begins. We also know that P53 is required to activate 
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p21 causing G2 arrest following DNA damage with IR (Bunz et al. 1998). The ATM 
pathway is extremely important because it serves as the interface where the cell fate is 
decided between apoptosis and senescence.  
             Over the past ten years, research has proven the DNA damage response to be 
more diverse and complicated than the activation of the proverbial ATM pathway in 
response to double-strand breaks. To date, 
five independent molecular complexes have 
been shown to sense and signal in response 
to various types of DNA damage. (Harper, 
Elledge 2007). For example, further 
upstream we know the three-member 
Mre11-Rad50-Nbs1 (MRN) complex 
directly detects DSB’s and recruits ATM to 
the compromised site of DNA (Lee et al. 
2005). This level of complexity indicates 
the broad array of molecular players that 
could be differentially regulated and 
activated in response to parity. 
                                                            
 
 
 
 
Figure 4.1a – Schematic showing 
how eukaryotic cells sense and 
respond to DSBs – the main type of 
DNA damage caused by IR. 
Oncogene (2003) 22, 5792–5812 
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Figure 4.1b – Schematic showing GG-
NER and TNER pathways in response to 
DNA damage from bulky lesions. Genes 
and Dev. (2002) 13:768–785. 
NER Pathways 
The nucleotide excision repair (NER) pathway is reported to be the most versatile 
DDR pathway and is responsible for removing a wide spectrum of bulky DNA lesions 
that distort the helical shape of DNA. 
Ultraviolet irradiation, antitumor drugs 
(cis-platin), and some toxins found in 
food are some of the environmental 
agents that can cause bulky lesions in 
DNA which can inhibit efficient 
replication and/or transcription 
(Maddukuri et al 2007). There are two 
distinct pathways comprising in the 
NER pathway: global genome repair 
(GGR) and transcription-coupled 
repair (TCR).   
As the name implies, GGR is 
responsible for sensing DNA damage 
throughout the entire genome via the 
XPC-hHR23B complex. Global 
Genome GG-NER is reliant upon the hHR23B sensing the bulky lesion, and recruiting 
other molecular players that act to repair the damaged strand. hHR23B then recruits and 
complexes with XPC (Sugasawa et al 1996). This complex then further distorts the helix, 
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recruits TFIIH, and the repair process commences (Evans et al 1997) This XPC complex 
then acts as the initiator of GGR (Sugasawa et al 1998).   
Transcription-coupled nucleotide excision repair (TC-NER) is a specialized 
pathway identified in the mid-1980’s by the Hanawalt lab. The TCR pathway is 
important for recognizing and removing lesions from the template strand actively being 
transcribed by RNA pol II. The stalled polymerase acts to signal further downstream to 
recruit and activate the assembly of other TC-NER proteins. TC-NER is of key 
importance to sense and bypass stalled transcription complexes in order to recover 
synthesis of the original mRNA molecule. Repair of any damage on the template strand 
relies upon active transcription. Chromatin relaxation is one of the first requisites of TC-
NER which serves to allow the NER machinery access to the damaged strand. NER 
genes are thought to be responsible for single strand break repair of large DNA adducts.    
CSB (also known as ERCC6) is a SWI2/SNF2 ATP dependent chromatin 
remodeling protein (Troelestra et al 1992, 1996). ERCC6 directs the excision nuclease to 
RNA polymerase stalled at a lesion in the transcribed strand and has shown to be 
upregulated in the parous breast of post-menopausal women (Russo et al 2007). ERCC8 
has been shown to be upregulated in the parous breast (Russo et al 2008). ERCC8 
encodes a WD domain-containing protein called CSA, and has been shown to interact 
with CSB (ERCC6) as well as RNAPolIIA. CSA is also shown to be the vital component 
of an E3 ubiquitin ligase complex (Groisman et al 2006). These two factors appear to 
work together in early transcription-coupled nucleotide excision repair, and it was also 
shown that CSB is one of the substrates used by the E3 ligase formed by CSA, which gets 
targeted for proteosomal degradation following activation of the TC-NER pathway 
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(Groisman 2006). CSB also interacts with Cullin4A are important for transcription 
coupled-nucleotide excision in particular. ERCC1 physically interacts with the XPF 
endonuclease (ERCC4) and this interaction catalyzes the 5’ incision of the damaged 
DNA strand (Choi et al 2005). Excision Repair Cross-Complementing Rodent Repair 
Group 2 (ERCC2) was shown to be persistently upregulated in the parous mammary 
gland (Russo et al 2007). ERCC2 is reported to be a vital component of nucleotide-
excision repair (NER) (Troelstra et. al 1992).   
Ribosomal Protein S3 (RPS3) functions as a DNA endonuclease intimately 
involved in the NER pathway. RPS3 has also been shown to be persistently upregulated 
in the parous mammary gland (Russo et al 2007). The RAD51-like 1 has single stranded 
DNA binding and ATPase capacity, is involved in the homologous recombination repair 
has also been shown to be persistently upregulated in response to parity (Baybrooke et al 
2000, Russo et al 2007). These aforementioned genes represent components in the first 
system to be called into play in response to a double strand break, and they represent a 
potential reservoir to which we may discover several potential players conveying the 
parity protective effect. 
Small nucleotide polymorphisms in the NER pathway genes may modify breast 
cancer risk. Polymorphisms in  ERCC2 have been suggested to modify the risk for breast 
cancer after low level radiation exposure in radiation technologists (Rajaraman 2008). A 
separate study of breast cancer cases versus controls in New York found that even in the 
absence of radiation, polymorphisms in ERCC2 are associated with a 25% increase in the 
odds ratio which may be further compounded by the presence of other polymorphisms in 
the NER pathway (Crew 2007). Lastly, polymorphisms in the NER pathways genes have 
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been suggested to modify the relationship between smoking and breast cancer in African 
American women (Mechanic 2006). Thus, there is plenty of indication that changes in the 
pathway could play a potential role in protecting against breast cancer 
We know that the DDR is vital to consider as several players in the DDR have 
previously been shown to be differentially regulated in the parous mammary gland. Many 
members comprising the nucleotide excision repair (NER) pathway are reported to be 
differentially regulated in the parous breast. Although this pathway is classically 
activated by UV radiation causing bulky bases such as thymidine -dimers, it is an 
important consideration of the DDR that is reported to be affected by parity.  
 
Materials and Methods 
 
Human Explants 
Women undergoing elective reduction mammoplasties were asked to enroll in our 
study and donate their excised tissue. Immediately following surgery, roughly 70 grams 
of normal breast tissue was procured and dissected under sterile conditions. Small 
portions (roughly 200mg), of stromal/epithelial tissue were grossly dissected from the 
surrounding adipose tissue, placed on a small piece of surgical foam, and cultured in 
phenol-free basal medium for 24 hours at 5% CO2 to allow for equilibration. The tissue 
culture was then exposed to 5Gy of ionizing radiation while a duplicate organ culture was 
left unirradiated as a control. The tissue was left in culture for the subsequent six hours to 
allow for uninterrupted changes in gene expression. Finally, the replicate tissues were 
fixed in formalin and flash frozen in liquid Nitrogen for immunohistochemical analysis 
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and RNA isolation, respectively. RNA was sent out for microarray analyses and 
Quantitative PCR was performed to confirm our results. 
Microarray 
RNA was isolated from whole mammary tissue using Qiagen Minikit according 
to manufacturer’s instructions. RNA was then eluted from the column with NFH20, 
measured with a Spectrophotometer, and sent to the Genomics Core University of North 
Carolina, Chapel Hill under the care of Dr. Melissa Troester where it was reverse 
transcribed and subject to microarray analysis. 
RT and QPCR 
 Total RNA from 50 mg of flash-frozen explants was isolated using TRIzol 
reagent (Invitrogen) standard protocol. Libraries were generated with QSCRIPT (Quanta 
Biosciences) using 100ng of total RNA as a template. Replicates were then diluted 1:10 
for QPCR analysis. Ten independent RT reactions were pooled together to account for 
variation in RT reaction, then serially diluted to generate a standard curve. Relative 
amounts of target genes and normalizer genes were determined by plotting the critical 
threshold (ct) values on their respective standard curve. To account for changes in a 
particular gene, the normalized levels from the unirradiated explant cDNA (control) was 
subtracted from the irradiated explant cDNA for each respective patient. 
 
Results 
 
Given there was less death seen in the parous breast, we decided to explore 
transcriptional responses of genes involved in the DDR, upstream of apoptosis. If there 
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was truly less death seen in the parous breast, we should see a heightened response in the 
systems involved in repairing compromised DNA.  Of the many genes tested, only genes 
involved in the NER pathway showed a statistically increased response after irradiation in 
the parous breast. In response to IR- ERCC1, ERCC2, ERCC6, and ERCC8 were 
significantly upregulated in the parous breast and downregulated or showed no change in 
the nulliparous breast. Other players such as ERCC4, and ERCC5 didn’t change 
significantly in response to IR between parous and nulliparous patients. Genes involved 
in the Base Excision Repair (BER) pathway all showed comparable responses between 
parous and nulliparous patient groups. Genes such as RPS3, XRCC2, XRCC6, and 
PARP1 all showed insignificant differences in expression when comparing parous to 
nulliparous tissues. 
 
 
Discussion 
 
The data produced by our TUNEL assay argued against our original hypothesis. It 
is interesting to note that Balb/c mice which have been frequently used to show parity 
induced sensitivity to death are mutant in some of their DNA repair capabilities. 
Although the genetic basis for this observation has yet to be elucidated, it was reported 
that the Balb/c strain of mice is deficient in DSB rejoining, which seems to be specific to 
the NHEJ pathway (Okayasu et al 2000). This deficiency in DDR could be the basis for 
why there was increased apoptosis in the mouse model. Opposite of what was reported in 
the mouse, the parous breast is actually less susceptible to IR induced apoptosis, while 
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the nulliparous breast showed an abrogated apoptotic response. Although this decreased 
sensitivity could be seen as a risk factor, there are various other mechanisms upstream of 
cell-death such as a heightened DDR that could be allowing the parous mammary gland 
to deal with genotoxic stress more efficiently. In order to test this hypothesis, we decided 
to test several genes involved in the DDR, reported to be differentially regulated in 
response to parity. We chose several genes involved in the NER such as ERCC1, 
ERCC2, ERCC6, and ERCC8. We also chose several genes involved in the BER pathway 
RPS3, RAD23, RAD51-Like1, XRCC2 and XRCC6, and PARP1. Interestingly, many of 
the NER pathway genes showed significantly different responses between the parous and 
nulliparous breast, all of the BER genes showed insignificant differences in response to 
IR. This suggests that whatever mechanism might be conveying this decreased sensitivity 
to IR induced death may very well be specific to the NER pathway. According to the 
literature, double stranded breaks are thought to activate the non-homologous end joining 
(NHEJ) pathway. The NHEJ pathway is comprised of numerous enzymes such as DNA-
PK, Ku70 and Ku80, which sense and form a complex at the site of the DSB, aligning 
short homologies in overhand regions, and the Ligase IV/XRCC4 complex that seals the 
break (Grawunder et al 1997). It was interesting that so many genes involved in the NER 
pathway were differentially regulated in response to IR.  As noted before, although an 
abrogated NER pathway has been reported multiple times in the literature to coincide 
with a reduced risk of breast cancer, IR is not the classically described perturbation used 
to activate this system. It is possible that IR could induce some single-stranded breaks in 
our system. Perhaps the ability of IR to cause the conversion of reactive oxygen species 
from water could be used to explain the induction of the NER pathways. 
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In general, the parous mammary gland seemed to have greater basal expression 
levels of ERCC1, and ERCC8 prior to irradiation. None of the differences seen in basal 
expression levels for the NER genes were significant, however the increased basal levels 
of transcript are certainly an important observation. ERCC1 for instance, is the excision 
nuclease that is vital for DNA cross-link repair. Increasing basal levels of these genes 
could be a mechanism by which the parous mammary gland abrogates the NER pathway. 
             Clusterin also deserves mention in this model, as it is well-documented that is the 
protein is activated by IR after double-stranded breaks. An exciting immunoprecipitation 
experiment determined that after short-term IR exposure, CLU coprecipitates with Ku70 
and Ku80 in MCF7 breast cancer cells, and signals for cell-death (Yang et al 1999). It 
would be interesting to see if the sensitivity that was seen in the nulliparous breast could 
be due to an increase in this association.  
The results presented inspire potential for many future experiments. It would be 
fascinating to further narrow these observations down to an enriched epithelial cell-type. 
Ideally, some of these experiments could involve isolating human mammary epithelial 
cells (HMECs) from our reduction mammoplasty tissues. These HMECs could serve as 
the bridge to a more targeted approach to identifying the protective factors conveyed at 
the level of the epithelium. The most promising route in these future directions involves 
the phenomenon seen in the NER genes and the DDR. One of the first assays we would 
like to do is an alkaline comet assay. Given that we saw an increased DDR in the parous 
breast, we would expect to see less cleaved DNA and a smaller “tail”, in the HMECs 
isolated from parous women. Likewise, if there truly is a propensity for the nulliparous 
65 
 
breast towards apoptosis as opposed to repairing the DNA, we would hope to see more 
damaged DNA and a larger “tail,” six hours following irradiation.  
 It would be interesting to see if the parity-dependent trends seen the NER 
pathway from our explants system could be repeated in an enriched HMEC culture. 
Initially, it would be necessary to choose the same 5 Gy dose and 6 hour timepoint. It 
would be fascinating to elaborate with earlier timepoints as perhaps one DDR pathway 
(NHEJ) is favored at an earlier timepoint, and whether or not these nuances in IR 
response are parity-dependent phenomenon. 
CLU would be a fascinating protein to study in this HMEC system. We would 
irradiate them, isolate nuclear protein lysate, immunoprecipitate CLU complexes, run and 
probe the precipitates on a western blot. We would ultimately like to see if more CLU-
Ku70 complexes were found in the nulliparous HMECs. A stronger band could be a great 
way to propose a sensitized death in the nulliparous patients, as the CLU-Ku70 
association should signal downstream to induce apoptosis or at the very least, G1 cell-
cycle arrest.   
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Figure 4.2- QPCR data showing increased expression levels of genes comprising 
the NER pathway in response to IR in parous explants. ERCC genes were chosen 
because ERCC2, ERCC6, and ERCC 8 were reported by Russo to be upregulated 
in the parous breast of post-menopausal women. (*denotes statistical significance) 
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Figure 4.3 – QPCR data depicting changes in expression of more genes involved in 
the nucleotide excision repair NER pathway after irradiation. * denotes statistical 
significance    
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Figure 4.4 – QPCR data depicting no significant change in genes involved with 
BER pathway between parous and nulliparous explants. BER genes were 
chosen because they were previously reported to be significantly upregulated in 
the parous breast by Russo. 
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Figure 4.5 – QPCR data depicting more genes involved in the BER pathway. No 
significant difference was seen between parous and nulliparous explants. The 
above genes were also reported by Russo to be persistently upregulated in the 
parous breast. 
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CHAPTER 5  
EXPERIMENTAL DESIGNS AND APPLICATIONS TO HUMAN TISSUE BANK 
Introduction 
Human Reduction Bank and Inherent Caveats 
 
 To date, 212 breast reduction specimens (both flash-frozen and paraffin 
embedded) have been collected; 180 of these specimens have corresponding interview 
information. Likewise, this bank represents an amazing resource with which to study the 
various factors and genes that determine susceptibility to breast cancer. A majority of this 
project was aimed at designing experiments and analyses around inherent caveats 
conveyed by sampling flaws in our patient populations. Additionally, as breast tissue is 
highly variable in composition between patients of different breast densities, age groups, 
reproductive history, etc., it creates further difficulties in deriving meaningful data from 
our bank. This chapter will address the various ways in which these confounders and 
caveats were considered in both experimental design and analyses of various 
experiments.  
The greatest amount of time on this project was spent on getting reliable QPCR 
data from our patient groups. A definite source of error accounting for this is as follows:  
our transcriptomic studies were done with mRNA derived from whole breast tissue. 
Whole breast tissue is highly heterogeneous, and this heterogeneity differs greatly from 
patient to patient. Similarly, whole mRNA isolations taken from this heterogeneous tissue 
are likely to be differentially representative of epithelial, stromal, adipose, and to a lesser 
extent, immune cells. Immediately, this heterogeneity should account for unwanted 
71 
 
variation within and between parous and nulliparous groups. Several groups, namely 
Russo got around this problem by using laser-capture micro dissection to preferentially 
isolate mammary epithelium from ducts, lobules, and terminal end buds (Balogh et. al 
2006).   
Another source of error comes from the fact that reduction tissue could very well 
be differentially representative of the breast itself based on where the surgeon 
preferentially dissected, and arbitrarily portioned the tissue for the study. Some portions 
could contain different amounts of ducts, terminal end buds, lobules, etc. For example, if 
the surgeon takes breast tissue more deep, nearer the pectoralus, we would expect the 
tissue to be enriched for secretory cells found in lobules. Conversely, if the tissue was 
excised more superficially, we would expect significantly ductal structures. Likewise, we 
should expect a large variation in the cell types comprising these various structures as 
each aforementioned part of the mammary gland serves distinct physiological roles. A 
large part of this drawback comes from the different areas of the breast that were excised 
and selected based on different surgeons with different techniques, varying from case to 
case. This different composition based on actual cell-type should also account for 
unwanted variation in our transcriptomic studies as does the different percent 
composition by (density of the) tissue. Both of these caveats should and have affected the 
extent to which we can evaluate and score protein levels in the specimens by IHC.  
There was a large age inequity between the parous and nulliparous patient groups. 
Nulliparous patients were 20 years younger on average than the parous patients. This 
greatly limited the number of patients we could use for comparison in experimental 
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analysis. A well designed experiment should test the same age groups of women, and 
examine parity as the sole variable affecting breast cancer risk.  
 The CDC estimates a 24 percent obesity-rate of women living in the state of 
Massachusetts. We should also expect that larger women have larger breasts on average, 
and would be more frequently getting breast reductions as compared to the rest of the 
population. Our database suggests this trend with 36 percent of our patients being obese, 
as determined by their body mass indices (BMIs). This 15 percent enrichment for obesity 
represents another inherent caveat in our sampling. This large discrepancy could greatly 
affect our ability to generalize any of our findings to the general public, as our tissue 
bank represents an extraordinary population. While many of our findings could be 
suggestive of certain protective dispositions, obesity has long been known as a potent risk 
factor for developing multiple different types of cancer. With this in mind we need to be 
cautious about our choice of words as the project while close, isn’t representative of the, 
“normal” breast. 
 Lastly, it should be mentioned that we were unable to determine where in their 
menstrual cycle the patients were at the time of surgery. Although this wasn’t built into 
our panel of interview information, including this question could have at least provided 
us a rough estimate as to where in their cycle each patient is. This information could 
possibly be more important than knowing the age of the patient as the mammary gland is 
highly estrogen (ER) and progesterone (PR) positive. Likewise, the mammary gland is by 
definition a “target tissue” for the hormones estrogen and progesterone. When bound to 
its respective receptor(s), these hormones are potent transcription factors that cause the 
transcription of many genes downstream of many different ER- or PR- specific 
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promoters. As the menstrual cycle is defined by monthly oscillations in circulating 
estrogen and progesterone levels, these variations should be significant confounders, 
particularly in a transcriptomic study. An example of this could be with the gene CLU, 
which was suggested by our microarray of 0-time tissues. Estradiol treatment of 
endometrial cells was reported to induce expression of CLU (Ahn et al 2008). Although 
designing our experiments around this factor would be severely limiting to the number 
viable patients could be included into our study, it could at the very least be used as an 
argument to discount any particular women that don’t fit a certain paradigm. As 
mentioned with CLU, preemptively including this confounder with our analysis could 
either confirm or refute this particular finding as it could have either made CLU (and 
many others) statistically significant, or it could have left it (an many others) completely 
unmentioned in our microarray. As mentioned previously, inhibin and activin α, βA, and 
βB subunits (both at the message and protein level) were reported to be present in normal 
breast tissue regardless of the time of the patient’s  menstrual cycle or menopause (Reis 
et al 2004). The estrous-independent expression of these genes suggests that these genes 
have an amazing potential and demand future exploration in our tissues, as they shouldn’t 
be affected by the circulating levels of estrogen and progesterone (E&P). 
 
Quantitative PCR and the Use of Suitable Normalizers 
 
 One of the best ways to derive meaningful transcriptomic data, regardless of the 
aforementioned sampling flaws associated with our bank is to use a normalizer that is 
both relevant and similar in abundance to the gene of interest. One of the first genes to be 
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used as a normalizer at the beginning of this project was GAPDH. This gene was chosen 
as it was classically described as a reliable and relatively stable metabolic gene with little 
variation associated between patients, or experimental groups. Recent literature now 
suggests that this gene is in fact significantly and persistently upregulated in the parous 
breast (Russo et al 2006). Likewise, as this gene is high in abundance, many of the genes 
we chose to explore were particularly low in abundance and would amplify 10-15 cycles 
downfield. 18srRNA was another gene initially used to normalize for our genes of 
interest. This gene was also widely used by Russo as a normalizer in order to verify their 
microarray data. Our findings show that this RNA is remarkably abundant and amplified 
well out of the acceptable range for our genes of interest.  Genes that seemed to show 
consistent, repeatable data were the cytokeratins, namely CK14, and CK18. As shown in 
figure 5.2, the overlap of a 1:3 CK18 standard curve is within the same range of most of 
our genes of interest, as seen with ERCC2. This overlap seems important as experiments 
designed with the appropriate normalizers produced repeatable results that seemed to 
align better with our microarray. Assays testing the bearing of normalizer on 
experimental outcome are demonstrated in figure 5.3. Not only can the normalizer 
completely change the outcome of the experiment, but it can also abrogate the findings of 
the assay. This factor is demonstrated by the scales seen on the y axes. The GAPDH 
assay suggests that the changes in TGFBetaII transcript are 2 fold larger in magnitude 
than the assays using 18SrRNA and CK18 as normalizers.  
 Towards the end of the project, many of the genes that we chose to analyze were 
predominately suggested by the literature, and not by the heatmaps generated by our 
microarray. Oddly enough, we were able to generate much more significant data by 
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looking at genes and markers suggested by journals than we were ever close to by trying 
to verify with microarray. For our particular tissue collection, and our particular system 
of isolating RNA, microarray, although very convenient and time-saving, may not be an 
appropriate assay based on the heterogeneity of our tissue. Likewise, with microarray 
analysis, RNA isolated from breast cancer cell lines were spiked onto a chip and used as 
normalizers to show whether or not a gene was high or low in expression. In addition, we 
had our microarray data analyzed independently via two different methods, by two 
different scientists, and this produced two radically different heat maps with very little 
overlap. Although by using two different microarray platforms allows for a stringent test 
that aligns with the status quo protocol published in the literature, it doesn’t correct for 
any the aforementioned variations seen in our tissue composition. Prospectively if we 
were to microdissect any of our flash frozen tissue to enrich for epithelium, microarray 
might be a much more suitable assay. As was learned by doing this project, reproducible 
transcriptomic data was acquired by performing QPCR analysis.   
 
Immunohistochemistry 
 The goal from the beginning of this project was to section and stain our paraffin 
embedded tissues with the hopes of showing differential percentages and intensities of 
various proteins in parous versus nulliparous women. Although we optimized numerous, 
highly-specific and reproducible staining protocols for many different antibodies, none of 
these studies showed differential staining in response to parity. One of our most extensive 
experiments was done by staining 67 patients for p53, and the intensity of both the 
luminal and myoepithelial cells were blindly scored independently by two pathologists 
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(data not shown). The results were insignificant even with this large number of patients 
chosen for analysis. Although many of the subsequent IHC’s were done with a much 
smaller number of patients, there were no appreciable differences in any of the tissues 
based on parity, age, etc. In addition to this, IHC tends to get very expensive, very 
quickly. 
 Although, IHC didn’t prove useful to show differential regulation of specific 
genes at the level of protein, IHC did answer a wealth of questions about certain 
characteristics of the respective gene of interest. For instance, when we stained for 
Betaglycan there was no appreciable difference in either staining or intensity of this 
protein between nulliparous and parous populations. After staining these tissues, it 
became apparent that a majority of its expression was localized to myoepithelial/basal 
epithelial cells. After discovering this attribute, we then used the myoepithelial/basal cell 
marker CK14 as a normalizer in our QPCR assay, and we were able to reproduce the 
trend originally seen in our microarray. Another important attribute this technique 
seemed to be useful for was timepoints of expression. For example, when we stained for 
p38 in our explants, it showed that much of the expression at the level of the protein took 
place at the very early time point of a half-hour. This is extremely important information 
as it verifies whether or not we are looking at the correct time to see differences in 
expression of particular genes.  Lastly, as we used IR to perturb our explants, IHC was 
extremely indicative of whether or not that specific gene was responsive to radiation. 
Again, it should be noted that this cause and effect relationship is dependent upon 
whether or not we fixed the explants at a relevant timepoint, but it did prove useful for 
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the most part to see whether or not a particular gene was upregulated or not in response to 
irradiation. 
In summary, IHC was important to this project to show whether or not as well as 
which specific tissues or cell types the particular gene is expressed. This technique also 
suggested whether or not the specific gene was IR-responsive, and at which time after 
irradiation we could expect to see induction of a certain gene. Conversely, IHC proved 
ineffective in our system to show differential expression levels of any genes that we’ve 
tested to date, at least when comparing parous versus nulliparous patient groups. In the 
future this technique may prove useful to flag cells that are existent in very small 
numbers. Immune cells have been reported to be existent in the mammary gland. Another 
potential use for IHC could involve another marker for death such as the M30. Having a 
highly specific stain for a ligand associated with apoptosis could prove to be a less-
subjective means for quantifying apoptosis. 
 
Paraffin Sections and TUNEL Assay 
 
One final note regarding the TUNEL study involves the integrity of the tissues 
produced at the end of this procedure. One of the prevailing problems of this assay was 
that many of the ductal structures produced from this procedure were completely 
collapsed. This phenomenon seemed to be a patient-specific. Some patients had perfectly 
intact ducts, while others compromised structures with epithelial cells spilling into the 
lumen. Interestingly, cells that were part of structurally compromised/collapsed ducts 
seemed to have significantly more signal than cells composing an intact duct. Although 
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all the tissues were procured, cultured, fixed, embedded, sectioned, and stained the same, 
some patients’ ducts seemed to have more structural integrity than others.  
This collapsing of the ducts could come from culturing for 24 hours, the fixation 
processes, and/or the actual TUNEL assay itself. Although supplementing a piece of 
mammary tissue with necessary nutrients enables us to keep it alive, there still was a 
great deal of stress put on our explants. Firstly, oxygen can only diffuse roughly 10 
microns through tissue. Our explants were pieces of whole breast tissue about 2 mm 
thick, so there could have been a fair amount of hypoxia occurring. This hypoxia could 
account for some of the compromised architecture. This observation could have also been 
attributed to the lack of suitable nutrients necessary to maintain a stable gland. Our 
phenol-free medium was very basic and didn’t contain any serum or additional growth 
factors. This basic lack of nutrients could have also caused the collapse of many of these 
structures. 
The fixation process could also be blamed for the structural deterioration of our 
tissue. Our tissue was fixed for 24 hours in NBF at 4C, and transferred to 70% ethanol at 
4C where it would sit indefinitely, (anywhere between a week to a several months) until 
they were processed, and embedded in paraffin. The time the tissues spent in ethanol 
varied greatly from patient to patient, which could account for some of variation. 
Intuitively, we would expect the tissues that spent the longest period of time in ethanol, to 
have the greatest deterioration. 
   The chemistry involved in the TUNEL assay requires that you permeabilize the 
tissue so the enzymes can properly perfuse the nucleus and access the DNA. The optimal 
amount permeabilization was achieved by dissolving the proteinase K 1:20 in a 10mM 
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Tris solution with a pH of 8.0. The proteinase K was left to digest the tissue at 37C for 15 
minutes, and this seemed to be the least amount of time required so that all tissues would 
be adequately permeabilized. During the optimization it became clear that certain women 
required less permeabilization, while some required more. This phenomenon did not 
seem to depend upon the parity status of the donor. This phenomenon made this assay 
extremely difficult to standardize. The tissues that inherently needed less 
permeabilization would get often get over-permeabilized. This is a caveat that could 
easily account for the destruction of the ducts. With all of the incubation and wash steps 
involved in this assay, this was likely the most prominent contributor to the destruction of 
the ductal architecture. We can say this with some degree of confidence based on the fact 
that similar sections were cut from the same paraffin embedded blocks and either stained 
for IHC or even simple H&E stains. Looking at these slides retrospectively, it seems as 
though while some of the ducts are compromised, none of them seem to be near the 
degree or severity as some of the slides produce by our TUNEL assay.  
Over 100 sections were cut and stained for TUNEL, and of those we could only 
count 28 based on the fact that they still had intact ducts. Although we might have been 
overly stringent by discounting so many slides, we felt as though we were justified as 
there did such a striking increase in the number of positive cells comprise collapsed 
ducts. If this were not taken into account, the data would have surely been radically 
different as well as unreliable. 
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Figure 5.1 – Amplification plots from standard curves showing the difference in 
abundance from commonly used normalize genes (leftmost) as well as some 
genes of interest (rightmost) explored in this project. 
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Figure 5.2 – Amplification from standard curves  showing large area of overlap 
between the normalizer (CK18) and gene of interest (ERCC1), emphasizing the 
importance of the normlizer having a similar abundance to the gene of interest. 
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Figure 5.3 - QPCR data demonstrating 
the gravity of selecting a proper 
normalizer to equalize the chosen gene of 
interest. All PCR reactions were between 
98 and 100% efficiency, however they 
differ only the normalize genes. 
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